BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on BridgeBio Oncology Therapeutics, with seven buy ratings and one sell rating among eight analysts. The average 12-month price target is $24.40, well above the stock’s $8.95 opening price.
• BBOT recently reported a quarterly loss of $705.20 per share, while analysts expect a full-year loss of approximately $2.32 per share. The stock trades near $8.95, with a one-year range of $7.00 to $14.87 and a market capitalization of about $717.5 million.
• Institutional investors own 54.89% of the company, with several firms increasing their positions or initiating new stakes, including Armistice Capital, Laurion Capital, and Paradigm Biocapital.

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) have earned an average rating of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $24.40.

Several equities research analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an "outperform" rating and a $22.00 price objective for the company. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, July 18th. JPMorgan Chase & Co. dropped their target price on BridgeBio Oncology Therapeutics from $27.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, August 14th. Canaccord Genuity Group started coverage on BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They set a "buy" rating and a $23.00 price target on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th.

BridgeBio Oncology Therapeutics Stock Performance

BridgeBio Oncology Therapeutics stock opened at $8.95 on Wednesday. BridgeBio Oncology Therapeutics has a one year low of $7.00 and a one year high of $14.87. The company has a 50-day simple moving average of $8.35 and a 200-day simple moving average of $8.99. The firm has a market capitalization of $717.52 million, a P/E ratio of -3.24 and a beta of 0.35.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. As a group, sell-side analysts forecast that BridgeBio Oncology Therapeutics will post -2.32 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Armistice Capital LLC lifted its stake in BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company's stock valued at $12,520,000 after buying an additional 588,000 shares in the last quarter. Laurion Capital Management LP raised its holdings in shares of BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company's stock worth $18,341,000 after acquiring an additional 419,138 shares in the last quarter. Catalio Capital Management LP acquired a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $5,142,000. Paradigm Biocapital Advisors LP grew its position in BridgeBio Oncology Therapeutics by 21.2% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company's stock worth $28,317,000 after acquiring an additional 395,608 shares in the last quarter. Finally, Granahan Investment Management LLC acquired a new position in BridgeBio Oncology Therapeutics during the first quarter worth $2,068,000. Institutional investors own 54.89% of the company's stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source